Provention Bio’s $2.9B Acquisition – A Strategic Fit For Sanofi
Sanofi SA (NASDAQ:SNY) has agreed to acquire Provention Bio Inc (NASDAQ:PRVB) for $25.00 per share in cash, representing an equity value of approximately…
Acadia Pharma’s Rett Syndrome Drug Becomes First FDA-Approved Treatment
The FDA has approved Acadia Pharmaceuticals Inc’s (NASDAQ:ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of…
Why Aridis Pharmaceuticals Shares Are Soaring Today
Aridis Pharmaceuticals Inc (NASDAQ:ARDS) announced preliminary topline results from the Phase 2a study of AR-501 in cystic fibrosis (CF) patients with…
Seagen’s $43B Deal To Double Pfizer’s Early-Stage Oncology Pipeline, Seagen Says Is Right Step
Pfizer Inc (NYSE:PFE) has agreed to acquire Seagen Inc (NASDAQ:SGEN) for $229 in cash per Seagen share for a total enterprise value…
Why Prevention Bio Stock Is Rocketing Past 52-Week Highs Today
Provention Bio Inc (NASDAQ: PRVB) shares are rocketing higher Monday after Sanofi (NASDAQ: SNY) announced plans to acquire the biopharmaceutical company.</
EXCLUSIVE: Hashing Out The Trailblazing Journey Of Roger Volodarsky And Puffco
The story of Puffco is the story of a man, his time and place, his passion for hashish and a team of creatives pushing his company forward. And it all started as a hobby when Vape pens set the scene in New York in 2012.
Jaguar Health Leveraging AI To Support Patient Access To Mytesi, The Company’s FDA-Approved Prescription Drug
AI technology is expected to help make it faster and easier for Mytesi® patients to start and stay on the drug
SAN FRANCISCO, CA / ACCESSWIRE / March 13, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX)
Pfizer Is Sending Seagen Stock Soaring Monday: What’s Going On?
Seagen Inc (NASDAQ: SGEN) shares are trading higher Monday after Pfizer Inc (NYSE: PFE) announced plans to acquire the global biotech company.
Eagle Pharmaceuticals Sees FY23 Adjusted EPS Of $4.20-$4.53 Vs. Consensus of $4.49
Expects 2023 Adjusted EBITDA of $74.0-$80.0 million